Compare Bristol-Myers Squibb Co (BMY) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Liberty Global Ltd Class C — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Liberty Global Ltd Class C trades at $10.4 (market cap $3.59B). The key difference: Bristol-Myers Squibb Co is far larger — about 32.4× Liberty Global Ltd Class C's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| BMY | LBTYK | |
|---|---|---|
Market Cap | $116.30B | $3.59B |
Sector | Health | Technology |
52-Week High | $62.37 | $12.67 |
52-Week Low | $42.60 | $10.07 |
Enterprise Value | $152.24B | $10.88B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
LBTYK trades at $10.54, up 2.63% today, but technical indicators are bearish with a negative net income margin of -109.66% for 2026. The stock shows a low P/S of 0.71 and P/B of 0.37, indicating potential undervaluation. Recent news highlights the planned 2027 spin-off and Amsterdam listing of Ziggo Group as a key catalyst. Analyst consensus is strongly positive with 69% buy ratings, though earnings have been volatile with a significant miss in Q4 2025.
The outlook is mixed: the spin-off offers upside potential, but persistent losses and high debt pose risks. Investors should weigh the sum-of-the-parts valuation opportunity against operational challenges and market volatility. The stock remains speculative with a bearish technical trend despite positive analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
